Hello - I received quite shocking news during my visit to the Mayo Clinic last week. My PSA has jumped to 344 from a low of 3.6 last November, when I completed chemo with cabazitaxel. PSA did start to rise quite soon, into double digits, but this is by far my highest PSA ever.
Dr. Kwon recommended starting chemo with taxotere plus carboplatin and this is scheduled to start in Cyprus on 17 June (the earliest appointment I could get). He also recommended adding Xtandi or Nubeqa, but the "protocols" at the oncology center here in Cyprus would not permit that, so we have agreed to skip it for now and see how the chemo goes. As noted in my previous postings, I had chemo with docetaxel in 2022, when PSA started at 62 ng/ml and fell to 8 ng/ml after six cycles. I started chemo with cabazitaxel in July 2023 when PSA was 83, and as reported above it had fallen to 3.6 by November 2023. I am on Zoladex shots every three months.
The latest Mayo report sums up: "Interval progression of intensely PSMA avid nodal and peritoneal metastases since 11/06/2023. miPSMA Expression Score 3."
PROSTATE BED: No abnormal PSMA uptake to suggest locally recurrent disease.
LYMPH NODES: Interval increase PSMA uptake of pelvic sdewall soft tissue left worse than right, with the most prominent soft tissue in the left posterior pelvic sidewall (SUV max: 15.2)
New PSMA avid left para-aortic lymph node (SUV max: 13.5)
OSSEOUS DISEASE: No PSMA avid osseous lesion.
OTHER METASTATIC DISEASE: Multifocal PSMA avid peritoneal and mesenteric nodularity, most prominently seen along the hepatic surface and the small bowel mesentery, highly suspicious for peritoneal metastases. For example, linear perihepatic lesion along the right hemidiaphragm (SUV max: 5.4) and focal soft tissue anterior to the left lateral hepatic lobe (SUV max 10.4)
Multifocal porta hepatis, periportal and gastrohepatic PSMA uptake without definite corresponding CT abnormality, indeterminant for nodal metastases versus peritoneal metastasis. For example, PSMA focus anterior to the caudate lobe (SUV max 11.7) and PSMA avid focus along the gastrohepatic ligament (SUV max: 9.5)
Stable PSMA activity within the bilateral thyroid lobes.
Reference SUV max:
- Parotid gland: 13.1
- Liver: 4.1
Additional findings on the noncontrast low-dose CT: Gynecomastia. Atherosclerotic calcification including coronary artery calcification. Pulmonary atelectasis. Colonic diverticulosis. Advanced musculoskeletal degenerative change with thoracolumbar curvature. Compression deformities of T11, T12, L4, L5. Transitional lumbosacral vertebra. Hepatic cysts. Colonic diverticula.
The Mayo report adds:
He will repeat genetic testing to determine if he has any targetable genetic mutations or high tumor burden for which he could qualify for potential treatment with a PARP inhibitor or immunotherapy in the future. (I gave a blood sample for testing before leaving the Mayo.)
I was instructed to return for follow-up after 3 to 4 cycles of chemo to assess treatment response to perform the following tests: PSA, Testosterone, Alkaline phosphatase, AST, ALT, Total Bilirubin, and Direct Bilirubin. In addition PSMA PET to identify sites of prostate cancer relapse after failed treatment, per medical necessity and per FDA, NCCN and CMS guidelines.
I would be interested in any comparable experiences. It seems quite unusual that PSA would make such a powerful comeback after last year's chemo with cabazitaxel and I wonder whether there's anything we could or should have done to ensure it stayed lower for longer.